A Phase I Single-Arm Study of the Combination of Durvalumab (MEDI4736) and Vicinium (Oportuzumab Monatox, VB4-845) in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With BCG

Trial Profile

A Phase I Single-Arm Study of the Combination of Durvalumab (MEDI4736) and Vicinium (Oportuzumab Monatox, VB4-845) in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With BCG

Recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Dec 2017

At a glance

  • Drugs Durvalumab (Primary) ; Oportuzumab monatox (Primary)
  • Indications Bladder cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 14 Dec 2017 Planned initiation date changed from 1 Dec 2017 to 19 Dec 2017.
    • 25 Nov 2017 Planned initiation date changed from 30 Nov 2017 to 1 Dec 2017.
    • 21 Nov 2017 Planned initiation date changed from 1 Nov 2017 to 27 Nov 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top